TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28588322

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus gemcitabine (G)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus gemcitabine and nab-paclitaxel (G+NP)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus gemcitabine and vinorelbine (G+V)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus irinotecan (I)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus liposomal doxorubicin (LD)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 49

Group type: COMPARATOR
Intervention: Immunotherapy alone
Number of subjects: 49
Study: 25733162

Group type: EXPERIMENTAL
Intervention: mLSG15 plus mogamulizumab
Number of subjects: 53

Group type: COMPARATOR
Intervention: mLSG15 alone
Number of subjects: 53
Study: 23561229

Group type: EXPERIMENTAL
Intervention: levomilnacipran SR 40 mg
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: levomilnacipran SR 80 mg
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: levomilnacipran SR 120 mg
Number of subjects: 724

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 724
Study: 21964877

Group type: EXPERIMENTAL
Intervention: Astaxanthin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 19327999

Group type: EXPERIMENTAL
Intervention: Localized muscle fatigue
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole-body fatigue
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (seated position for 5 min)
Number of subjects: 20
Study: 16704567

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 24
Study: 14514977

Group type: EXPERIMENTAL
Intervention: IFN‐gamma 0.1 mg/m2 weekly (arm A)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: IFN‐gamma 0.3 mg/m2 iv daily x 5 every 3 weeks plus IFN‐alpha 10 MU/m2 daily (arm B)
Number of subjects: 95

Group type: COMPARATOR
Intervention: IFN‐gamma alone
Number of subjects: 95
Study: 11051055

Group type: EXPERIMENTAL
Intervention: Glimepiride administration
Number of subjects: 0
Study: 8956931

Group type: EXPERIMENTAL
Intervention: Home-made modular diet (MD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Semi-elemental formula (SF)
Number of subjects: 18
Study: 1539732

Group type: EXPERIMENTAL
Intervention: CCK‐8 infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 17
Study: 3963030

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (73 patients) administered two, three, or four times a day in total daily doses of 100, 150, or 200 mg
Number of subjects: 147

Group type: COMPARATOR
Intervention: Aspirin (74 patients) administered two, three, or four times a day in total daily doses of 2,000, 3,000, or 4,000 mg
Number of subjects: 147
Study: 31299774

Group type: EXPERIMENTAL
Intervention: Ridge-split technique with horizontal augmentation using autogenous bone graft
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ridge-split method with simultaneous implant placement
Number of subjects: 14
Study: 28298182

Group type: EXPERIMENTAL
Intervention: new electrocardiogram
Number of subjects: 65

Group type: COMPARATOR
Intervention: conventional electrocardiogram
Number of subjects: 65
Study: 25577190

Group type: EXPERIMENTAL
Intervention: Group CBT for psychosis (CBTp)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 113
Study: 24078500

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac sodium (1 mg/kg) 45 minutes before the procedure
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: EMLA cream (10 gm) applied locally 45 minutes before the procedure
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Diclofenac diethylamine gel (15 gm) applied locally 45 minutes before the procedure
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 105
Study: 21808866

Group type: EXPERIMENTAL
Intervention: Radioguided occult lesion localization (ROLL)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Wire-guided localization
Number of subjects: 108
Study: 18330545

Group type: EXPERIMENTAL
Intervention: Current opioid users
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Abstinent opioid users
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 63
Study: 16469456

Group type: EXPERIMENTAL
Intervention: Indomethacin prophylaxis
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study: 12616584

Group type: EXPERIMENTAL
Intervention: Eating Disorder Inventory (EDI‐2) assessment in infertile patients
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison with fertile women
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison with patients suffering from anorexia nervosa (AN‐R)
Number of subjects: 120
Study: 11781629

Group type: EXPERIMENTAL
Intervention: 1.8 g/day of eicosapentaenoic acid (EPA) orally from 3 weeks before to about 180 days after transplantation
Number of subjects: 16

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.8 g/day of eicosapentaenoic acid (EPA)
Number of subjects: 16
Study: 9260858

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 10
Study: 7923485

Group type: EXPERIMENTAL
Intervention: Incontinent patients with rectal prolapse
Number of subjects: 31

Group type: COMPARATOR
Intervention: Continent patients with rectal prolapse
Number of subjects: 31
Study: 3619975

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29705992

Group type: EXPERIMENTAL
Intervention: Oral antibiotics
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous antibiotics followed by oral antibiotics
Number of subjects: 25
Study: 27344435

Group type: EXPERIMENTAL
Intervention: Balloon-expandable cobalt-chromium SCUBA™ stent
Number of subjects: 280

Group type: COMPARATOR
Intervention: Self-expanding COMPLETE-SE™ nitinol stent
Number of subjects: 280
Study: 22672673

Group type: EXPERIMENTAL
Intervention: Weighted sled (WS) training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unresisted (UR) training
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 23464594

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 21569168

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) biomarker panel assessment (CK-MB, myoglobin, and troponin, measured at baseline and 90 minutes)
Number of subjects: 2243

Group type: COMPARATOR
Intervention: Standard care without the POC panel
Number of subjects: 2243

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) biomarker panel assessment
Number of subjects: 2243

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2243

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) panel
Number of subjects: 2243
Study: 19103332

Group type: EXPERIMENTAL
Intervention: Preload meal constituted 1/2 portion of pasta
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Preload meal constituted 1 portion of pasta
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Preload meal constituted 1 1/2 portions of pasta
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Portion size information
Number of subjects: 33
Study: 17057294

Group type: EXPERIMENTAL
Intervention: Vitamins and dietary supplements (vit. E, beta-carotene, acetylsalicylic acid) in combination with treatment measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopplerometric research
Number of subjects: 0
Study: 12696990

Group type: EXPERIMENTAL
Intervention: Orlistat, 120 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diabetes therapy and weight management alone (Control)
Number of subjects: 0
Study: 10702450

Group type: COMPARATOR
Intervention: Epidural droperidol 0.0 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Epidural droperidol 1.25 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Epidural droperidol 2.5 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Epidural droperidol 5.0 mg
Number of subjects: 140
Study: 9080303

Group type: EXPERIMENTAL
Intervention: cM-T412 (chimeric CD4 monoclonal antibody)
Number of subjects: 0
Study: 7677972

Group type: EXPERIMENTAL
Intervention: Experimental intervention (LBWE) - seven hospital sessions and four home sessions with a nurse
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Experimental intervention (LBWE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (LBWC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Normal birth weight children
Number of subjects: 24
Study: 3812881

Group type: EXPERIMENTAL
Intervention: HDCSV intramuscularly at two sites on days 0 and 3
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional single-site intramuscular regimen
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 0.25 ml doses of diploid cell vaccine given subcutaneously at eight sites
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Standard single-site diploid cell vaccine
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Eight-site intradermal regimen of diploid cell vaccine
Number of subjects: 118
Study: 30400892

Group type: EXPERIMENTAL
Intervention: Hybrid toothbrush (Elgydium Clinic/Inava Hybrid) used in combined mode
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oscillating-rotating toothbrush (Oral-B Vitality)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both toothbrushes
Number of subjects: 66
Study: 26987887

Group type: EXPERIMENTAL
Intervention: Plant-based quadrivalent virus-like particle (QVLP) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24957311

Group type: EXPERIMENTAL
Intervention: Cognitive impairment assessment using MMSE-M and TICS-M scales
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Cognitive impairment related to increasing age, stroke severity, heart rate, and cerebral atrophy
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: TICS-M related to dependency (modified Rankin Scale)
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: TICS-M related to disability (Barthel Index)
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: TICS-M related to mood (Zung Depression Score)
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: TICS-M related to quality of life (Euro Quality of life-5 Descriptor)
Number of subjects: 1572
Study: 22912868

Group type: EXPERIMENTAL
Intervention: Clostridium Histolyticum collagenase (CHC)
Number of subjects: 12
Study: 19890274

Group type: EXPERIMENTAL
Intervention: Epoetin-alfa treatment with high hemoglobin target (13.5 g/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epoetin-alfa treatment with low hemoglobin target (11.3 g/l)
Number of subjects: 0
Study: 18772726

Group type: EXPERIMENTAL
Intervention: Oxycodone (0.2 mg/kg; maximum 15 mg)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Codeine (2 mg/kg; maximum 120 mg)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Codeine
Number of subjects: 107
Study: 20655807

Group type: EXPERIMENTAL
Intervention: RBC units stored for 10 days or fewer
Number of subjects: 1434

Group type: COMPARATOR
Intervention: RBC units stored for 21 days or more
Number of subjects: 1434
Study: 15627208

Group type: EXPERIMENTAL
Intervention: Arm cranking at 60% of peak oxygen uptake (AC(60))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined arm cranking and leg cycling at 20% of VO(2peak) (AC(60)LC(20))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined arm cranking and leg cycling at 40% of VO(2peak) (AC(60)LC(40))
Number of subjects: 8
Study: 12380919

Group type: EXPERIMENTAL
Intervention: Unipolar plus bipolar recordings
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bipolar recordings
Number of subjects: 44
Study: 9637189

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg x kg(‐1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7865932

Group type: EXPERIMENTAL
Intervention: Videotaped behavioral treatment program
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo program
Number of subjects: 66

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 66
Study: 2492748

Group type: EXPERIMENTAL
Intervention: 750 mg of penicillin V once daily for ten days
Number of subjects: 154

Group type: COMPARATOR
Intervention: 250 mg of penicillin V three times daily for ten days
Number of subjects: 154
Study: 1058303

Group type: EXPERIMENTAL
Intervention: 0.02% iodine mouthwash
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Topical application of iodine solution (2.0% I2 and 2.4% NaI) with brushing and flossing
Number of subjects: 36

Group type: COMPARATOR
Intervention: Brushing and flossing only
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Topical application of iodine solution only
Number of subjects: 36

Group type: COMPARATOR
Intervention: Topical application of distilled water only
Number of subjects: 36
Study: 11235558

Group type: EXPERIMENTAL
Intervention: Albendazole (10 mg/kg.day for 5 days)
Number of subjects: 0
Study: 31342470

Group type: EXPERIMENTAL
Intervention: Gist condition responses
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-GIS versions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discussion sections of psychology journal articles
Number of subjects: 0

Group type: COMPARATOR
Intervention: News reports
Number of subjects: 0
Study: 29995761

Group type: EXPERIMENTAL
Intervention: Intracutaneous injection of local anesthetics (lidocaine and bupivacaine) and steroid (methylprednisolone)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ibuprofen (IPB group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intracutaneous injection of local anesthetics and steroids (MLB group)
Number of subjects: 36
Study: 27296978

Group type: EXPERIMENTAL
Intervention: ARTAS intervention for drug users with a treatment history
Number of subjects: 295

Group type: COMPARATOR
Intervention: ARTAS intervention for drug users without a treatment history
Number of subjects: 295
Study: 24893214

Group type: EXPERIMENTAL
Intervention: Pea protein
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Egg-white protein
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Maltodextrin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Milk protein
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 48

Group type: COMPARATOR
Intervention: Protein mix
Number of subjects: 48
Study: 22586483

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2500 IU daily for 4 months
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2500 IU
Number of subjects: 114
Study: 20828221

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 35
Study: 17420604

Group type: EXPERIMENTAL
Intervention: Yogurt containing 3.0 or 4.0 g of KM‐CW/d for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yogurt containing 3.0 or 4.0 g of KM‐CW/d
Number of subjects: 0
Study: 15793437

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 30
Study: 12027255

Group type: EXPERIMENTAL
Intervention: Er:YAG laser scaling
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional scaling and root planing or ultrasonic instruments
Number of subjects: 40
Study: 10622037

Group type: EXPERIMENTAL
Intervention: EFV + AZT + 3TC
Number of subjects: 0

Group type: COMPARATOR
Intervention: IDV + AZT + 3TC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EFV + IDV
Number of subjects: 0
Study: 7861019

Group type: EXPERIMENTAL
Intervention: Zidovudine (nucleoside reverse transcriptase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior zidovudine therapy
Number of subjects: 0
Study: 1682356

Group type: EXPERIMENTAL
Intervention: Misoprostol combined with H2RA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AG-1749 (proton-pump inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: H2-receptor antagonists (H2RAs)
Number of subjects: 0
Study: 7011526

Group type: EXPERIMENTAL
Intervention: Modern low-dose mammography screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study: 31972587

Group type: EXPERIMENTAL
Intervention: Topical insulin (Actrapid) 10 units (0.1 mL) in 1 mL of normal saline, applied twice daily.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Topical normal saline (placebo).
Number of subjects: 42
Study: 29726627

Group type: EXPERIMENTAL
Intervention: Patient-reported swelling (any swelling vs none)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Patient-reported constant swelling (versus none or intermittent)
Number of subjects: 276
Study: 28624041

Group type: EXPERIMENTAL
Intervention: Replacing saline solution during surgery (experimental group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline not replaced during surgery (control group)
Number of subjects: 52
Study: 25714536

Group type: EXPERIMENTAL
Intervention: Simulation Group (Eye Retinopathy Trainer®)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control Group (traditional method)
Number of subjects: 90
Study: 24700991

Group type: EXPERIMENTAL
Intervention: Group 1 - breastfeeding deferred for at least 1 hour before and after each dose of rotavirus vaccine
Number of subjects: 204

Group type: COMPARATOR
Intervention: Group 2 - unrestricted breastfeeding encouraged
Number of subjects: 204
Study: 22863242

Group type: EXPERIMENTAL
Intervention: Cinacalcet-based regimen
Number of subjects: 552

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Achieved iPTH ≤ 300 pg/mL
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Did not achieve iPTH ≤ 300 pg/mL
Number of subjects: 552
Study: 19085634

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g daily)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 17726611

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg in 1 ml subcutaneously twice a week for 2 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 12
Study: 14978006

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12166713

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.3% triclosan and essential oil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 9534101

Group type: EXPERIMENTAL
Intervention: Verapamil-trandolapril
Number of subjects: 100

Group type: COMPARATOR
Intervention: Trandolapril
Number of subjects: 100
Study: 7713812

Group type: EXPERIMENTAL
Intervention: Exercise in the morning (1130)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise in the afternoon (1630)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise in December (darkness period)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise in April (18 h of daylight)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Females during exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Analysis of variance for sex, time of exercise, and season
Number of subjects: 20
Study: 2569993

Group type: EXPERIMENTAL
Intervention: 8 mg/day azelastine once daily
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 8 mg/day azelastine twice daily
Number of subjects: 111

Group type: COMPARATOR
Intervention: 1 mg ketotifen twice daily
Number of subjects: 111
Study: 863837

Group type: EXPERIMENTAL
Intervention: 250 mg ascorbic acid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 500 mg ascorbic acid
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30401528

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127

Group type: EXPERIMENTAL
Intervention: Aspirin (low European System for Cardiac Operative Risk Evaluation score)
Number of subjects: 2127
Study: 27351896

Group type: EXPERIMENTAL
Intervention: ABM‐500 (500 ms stimulus duration; n=28)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: ABM‐1250 (1250 ms stimulus duration; n=26)
Number of subjects: 81

Group type: COMPARATOR
Intervention: ABM‐Placebo (sham training; n=27)
Number of subjects: 81
Study: 26316026

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (IHGE) at 50% of maximal voluntary contraction (8 min/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 140 ml/day of concentrated beetroot juice
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 30
Study: 24150234

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 1088
Study: 21276218

Group type: EXPERIMENTAL
Intervention: Exercise commercials
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control commercials (neutral products)
Number of subjects: 125
Study: 19813461

Group type: EXPERIMENTAL
Intervention: Test formulation of ramipril (10 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reference formulation of ramipril (10 mg)
Number of subjects: 40
Study: 17725471

Group type: EXPERIMENTAL
Intervention: Weight-bearing strengthening program
Number of subjects: 88

Group type: COMPARATOR
Intervention: Non-weight-bearing strengthening program
Number of subjects: 88
Study: 15213206

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/d
Number of subjects: 7479

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens plus medroxyprogesterone acetate (MPA) 0.625 mg/d + 2.5 mg/d
Number of subjects: 7479

Group type: EXPERIMENTAL
Intervention: Combined data from estrogen-alone and estrogen plus progestin trials
Number of subjects: 7479

Group type: EXPERIMENTAL
Intervention: Combined trial data
Number of subjects: 7479